383 related articles for article (PubMed ID: 11476261)
1. Gamma hydroxybutyrate (GHB) and gamma butyrolactone (GBL) withdrawal: five case studies.
McDaniel CH; Miotto KA
J Psychoactive Drugs; 2001; 33(2):143-9. PubMed ID: 11476261
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological Treatment in γ-Hydroxybutyrate (GHB) and γ-Butyrolactone (GBL) Dependence: Detoxification and Relapse Prevention.
Kamal RM; van Noorden MS; Wannet W; Beurmanjer H; Dijkstra BA; Schellekens A
CNS Drugs; 2017 Jan; 31(1):51-64. PubMed ID: 28004314
[TBL] [Abstract][Full Text] [Related]
3. Inpatient management of GHB/GBL withdrawal.
Delic M
Psychiatr Danub; 2019 Sep; 31(Suppl 3):354-356. PubMed ID: 31488752
[TBL] [Abstract][Full Text] [Related]
4. Psychiatric aspects of acute withdrawal from gamma-hydroxybutyrate (GHB) and its analogue gamma-butyrolactone (GBL): implications for psychiatry services in the general hospital.
Choudhuri D; Cross S; Dargan PI; Wood DM; Ranjith G
Int J Psychiatry Clin Pract; 2013 Jun; 17(2):154-6. PubMed ID: 23485126
[TBL] [Abstract][Full Text] [Related]
5. Management and treatment of gamma butyrolactone withdrawal syndrome: a case report and review.
Ghio L; Cervetti A; Respino M; Belvederi Murri M; Amore M
J Psychiatr Pract; 2014 Jul; 20(4):294-300. PubMed ID: 25036586
[TBL] [Abstract][Full Text] [Related]
6. [Gamma-hydroxybutyric acid (GHB) dependence and the GHB withdrawal syndrome: diagnosis and treatment].
van Noorden MS; Kamal R; de Jong CA; Vergouwen AC; Zitman FG
Ned Tijdschr Geneeskd; 2010; 154():A1286. PubMed ID: 21040601
[TBL] [Abstract][Full Text] [Related]
7. Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: a case report and systematic review.
Wojtowicz JM; Yarema MC; Wax PM
CJEM; 2008 Jan; 10(1):69-74. PubMed ID: 18226321
[TBL] [Abstract][Full Text] [Related]
8. [Withdrawal syndrome after abuse of GHB (Gamma-Hydroxybutyrate) and its physiological precursors - its relevance for child and adolescent psychiatrists].
Zepf FD; Holtmann M; Duketis E; Maier J; Radeloff D; Schirman S; Wagner A; Poustka F; Wöckel L
Z Kinder Jugendpsychiatr Psychother; 2009 Sep; 37(5):413-20. PubMed ID: 19739059
[TBL] [Abstract][Full Text] [Related]
9. Chronic intragastric administration of gamma-butyrolactone produces physical dependence in baboons.
Goodwin AK; Griffiths RR; Brown PR; Froestl W; Jakobs C; Gibson KM; Weerts EM
Psychopharmacology (Berl); 2006 Nov; 189(1):71-82. PubMed ID: 17047936
[TBL] [Abstract][Full Text] [Related]
10. Gamma-hydroxybutyrate withdrawal syndrome.
Dyer JE; Roth B; Hyma BA
Ann Emerg Med; 2001 Feb; 37(2):147-53. PubMed ID: 11174231
[TBL] [Abstract][Full Text] [Related]
11. Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence.
Galloway GP; Frederick SL; Staggers FE; Gonzales M; Stalcup SA; Smith DE
Addiction; 1997 Jan; 92(1):89-96. PubMed ID: 9060200
[TBL] [Abstract][Full Text] [Related]
12. The behavioural profile of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol in humans.
Bosch OG; Seifritz E
Brain Res Bull; 2016 Sep; 126(Pt 1):47-60. PubMed ID: 26855327
[TBL] [Abstract][Full Text] [Related]
13. Gamma hydroxybutyrate (GHB), gamma butyrolactone (GBL) and 1,4-butanediol (1,4-BD; BDO): A literature review with a focus on UK fatalities related to non-medical use.
Corkery JM; Loi B; Claridge H; Goodair C; Corazza O; Elliott S; Schifano F
Neurosci Biobehav Rev; 2015 Jun; 53():52-78. PubMed ID: 25843781
[TBL] [Abstract][Full Text] [Related]
14. The clinical toxicology of γ-hydroxybutyrate, γ-butyrolactone and 1,4-butanediol.
Schep LJ; Knudsen K; Slaughter RJ; Vale JA; Mégarbane B
Clin Toxicol (Phila); 2012 Jul; 50(6):458-70. PubMed ID: 22746383
[TBL] [Abstract][Full Text] [Related]
15. Pentobarbital for severe gamma-butyrolactone withdrawal.
Sivilotti ML; Burns MJ; Aaron CK; Greenberg MJ
Ann Emerg Med; 2001 Dec; 38(6):660-5. PubMed ID: 11719746
[TBL] [Abstract][Full Text] [Related]
16. Medical and legal confusion surrounding gamma-hydroxybutyrate (GHB) and its precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4BD).
Wood DM; Warren-Gash C; Ashraf T; Greene SL; Shather Z; Trivedy C; Clarke S; Ramsey J; Holt DW; Dargan PI
QJM; 2008 Jan; 101(1):23-9. PubMed ID: 18203723
[TBL] [Abstract][Full Text] [Related]
17. Acute toxicity and withdrawal syndromes related to γ-hydroxybutyrate (GHB) and its analogues γ-butyrolactone (GBL) and 1,4-butanediol (1,4-BD).
Wood DM; Brailsford AD; Dargan PI
Drug Test Anal; 2011; 3(7-8):417-25. PubMed ID: 21548140
[TBL] [Abstract][Full Text] [Related]
18. Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review.
McDonough M; Kennedy N; Glasper A; Bearn J
Drug Alcohol Depend; 2004 Jul; 75(1):3-9. PubMed ID: 15225884
[TBL] [Abstract][Full Text] [Related]
19. The gamma-hydroxybutyrate withdrawal syndrome.
Tarabar AF; Nelson LS
Toxicol Rev; 2004; 23(1):45-9. PubMed ID: 15298492
[TBL] [Abstract][Full Text] [Related]
20. Gamma-butyrolactone (GBL) dependence and withdrawal.
Bell J; Collins R
Addiction; 2011 Feb; 106(2):442-7. PubMed ID: 20925687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
